# A Study of Safety, Tolerability, and Evidence of Activity of FCFD4514S Administered Monthly or Every Other Month to Patients With Geographic Atrophy

> **NCT01229215** · PHASE2 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 143 (actual)

## Conditions studied

- Geographic Atrophy

## Interventions

- **DRUG:** FCFD4514S
- **DRUG:** sham

## Key facts

- **NCT ID:** NCT01229215
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 143 (ACTUAL)
- **Last updated:** 2016-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01229215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01229215, "A Study of Safety, Tolerability, and Evidence of Activity of FCFD4514S Administered Monthly or Every Other Month to Patients With Geographic Atrophy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01229215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*